Ultra-long-acting Tunable Biodegradable and Removable Controlled Release Implants for Drug Delivery

Overview

Journal Nat Commun

Specialty Biology

Date 2019 Sep 22

PMID 31541085

Citations 43

Authors

S Rahima Benhabbour

Martina Kovarova

Clinton Jones

Daijha J Copeland

Roopali Shrivastava

Michael D Swanson

Craig Sykes

Phong T Ho

Mackenzie L Cottrell

Anush Sridharan

Samantha M Fix

Orrin Thayer

Julie M Long

Daria J Hazuda

Paul A Dayton

Russell J Mumper

Angela D M Kashuba

J Victor Garcia

Affiliations

Soon will be listed here.

Abstract

Here we report an ultra-long-acting tunable, biodegradable, and removable polymer-based delivery system that offers sustained drug delivery for up to one year for HIV treatment or prophylaxis. This robust formulation offers the ability to integrate multiple drugs in a single injection, which is particularly important to address the potential for drug resistance with monotherapy. Six antiretroviral drugs were selected based on their solubility in N-methyl-2-pyrrolidone and relevance as a combination therapy for HIV treatment or prevention. All drugs released with concentrations above their protein-adjusted inhibitory concentration and retained their physical and chemical properties within the formulation and upon release. The versatility of this formulation to integrate multiple drugs and provide sustained plasma concentrations from several weeks to up to one year, combined with its ability to be removed to terminate the treatment if necessary, makes it attractive as a drug delivery platform technology for a wide range of applications.

Citing Articles

From Burst to Sustained Release: The Effect of Antibiotic Structure Incorporated into Chitosan-Based Films.

Sczesny N, Wiggers H, Bueno C, Chevallier P, Copes F, Mantovani D Antibiotics (Basel). 2024; 13(11).

PMID: 39596749 PMC: 11591004. DOI: 10.3390/antibiotics13111055.

Intracalvariosseous administration of donepezil microspheres protects against cognitive impairment by virtue of long-lasting brain exposure in mice.

Kang J, Yang J, Cho K, Lee O, Kwon H, Kim S Theranostics. 2024; 14(17):6708-6725.

PMID: 39479440 PMC: 11519799. DOI: 10.7150/thno.100986.

In vitro and in vivo evaluation of in situ forming polyester implants for the extended release of carvedilol.

Abulateefeh S, Abuhamdan R, Saed H, Alsalem M, Shnewer K Drug Deliv Transl Res. 2024; .

PMID: 39313736 DOI: 10.1007/s13346-024-01706-7.

Ultra-Long-Term Delivery of Hydrophilic Drugs Using Injectable Cross-Linked Depots.

Lee S, Zhao S, Jiang W, Chen X, Zhu L, Joseph J bioRxiv. 2024; .

PMID: 39253509 PMC: 11382995. DOI: 10.1101/2023.11.04.565631.

Therapeutic coordination polymers: tailoring drug release through metal-ligand interactions.

Murphy J, Kobti J, Dao M, Wear D, Okoko M, Pandey S Chem Sci. 2024; 15(19):7041-7050.

PMID: 38756811 PMC: 11095386. DOI: 10.1039/d4sc00732h.

References

Anstett K, Mesplede T, Oliveira M, Cutillas V, Wainberg M . Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions. J Virol. 2015; 89(8):4681-4. PMC: 4442391. DOI: 10.1128/JVI.03485-14. View

Prabhu S, Tran L, Betageri G . Effect of co-solvents on the controlled release of calcitonin polypeptide from in situ biodegradable polymer implants. Drug Deliv. 2005; 12(6):393-8. DOI: 10.1080/10717540590968873. View

Buchanan A, Holton M, Conn I, Davies M, Choukour M, Wynne B . Relative Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low- and High-Mineral-Content Water on the Tablet in Healthy Adults. Clin Pharmacol Drug Dev. 2017; 6(6):577-583. PMC: 5697680. DOI: 10.1002/cpdd.332. View

Makadia H, Siegel S . Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2012; 3(3):1377-1397. PMC: 3347861. DOI: 10.3390/polym3031377. View

Raheem I, Walji A, Klein D, Sanders J, Powell D, Abeywickrema P . Correction to Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors. J Med Chem. 2015; 59(1):486. DOI: 10.1021/acs.jmedchem.5b01957. View

Al-Tahami K, Singh J . Smart polymer based delivery systems for peptides and proteins. Recent Pat Drug Deliv Formul. 2008; 1(1):65-71. DOI: 10.2174/187221107779814113. View

Jouyban A, Fakhree M, Shayanfar A . Review of pharmaceutical applications of N-methyl-2-pyrrolidone. J Pharm Pharm Sci. 2011; 13(4):524-35. DOI: 10.18433/j3p306. View

Keele B, Giorgi E, Salazar-Gonzalez J, Decker J, Pham K, Salazar M . Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008; 105(21):7552-7. PMC: 2387184. DOI: 10.1073/pnas.0802203105. View

Brodbeck K, DesNoyer J, McHugh A . Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release. 1999; 62(3):333-44. DOI: 10.1016/s0168-3659(99)00159-5. View

10.

Guo J, Wang J, Cai C, Xu J, Yu H, Xu H . The anti-melanoma efficiency of the intratumoral injection of cucurbitacin-loaded sustained release carriers: in situ-forming implants. AAPS PharmSciTech. 2015; 16(4):973-85. PMC: 4508284. DOI: 10.1208/s12249-015-0292-2. View

11.

Patel R, Carlson A, Solorio L, Exner A . Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. J Biomed Mater Res A. 2010; 94(2):476-84. PMC: 2914550. DOI: 10.1002/jbm.a.32724. View

12.

DesNoyer J, McHugh A . Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems. J Control Release. 2001; 70(3):285-94. DOI: 10.1016/s0168-3659(00)00354-0. View

13.

Permar S, Salazar M, Gao F, Cai F, Learn G, Kalilani L . Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. Retrovirology. 2013; 10:88. PMC: 3765243. DOI: 10.1186/1742-4690-10-88. View

14.

Kovarova M, Council O, Date A, Long J, Nochi T, Nochii T . Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog. 2015; 11(8):e1005075. PMC: 4536200. DOI: 10.1371/journal.ppat.1005075. View

15.

Agarwal P, Rupenthal I . Injectable implants for the sustained release of protein and peptide drugs. Drug Discov Today. 2013; 18(7-8):337-49. DOI: 10.1016/j.drudis.2013.01.013. View

16.

Liang J, Mesplede T, Oliveira M, Anstett K, Wainberg M . The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance. J Virol. 2015; 89(22):11269-74. PMC: 4645644. DOI: 10.1128/JVI.01881-15. View

17.

Huang C, Chia W, Chung M, Lin K, Hsiao C, Jin C . An Implantable Depot That Can Generate Oxygen in Situ for Overcoming Hypoxia-Induced Resistance to Anticancer Drugs in Chemotherapy. J Am Chem Soc. 2016; 138(16):5222-5. DOI: 10.1021/jacs.6b01784. View

18.

Karfeld-Sulzer L, Ghayor C, Siegenthaler B, de Wild M, Leroux J, Weber F . N-methyl pyrrolidone/bone morphogenetic protein-2 double delivery with in situ forming implants. J Control Release. 2015; 203:181-8. DOI: 10.1016/j.jconrel.2015.02.019. View

19.

Eliaz R, Kost J . Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J Biomed Mater Res. 2000; 50(3):388-96. DOI: 10.1002/(sici)1097-4636(20000605)50:3<388::aid-jbm13>3.0.co;2-f. View

20.

McHugh A . The role of polymer membrane formation in sustained release drug delivery systems. J Control Release. 2005; 109(1-3):211-21. DOI: 10.1016/j.jconrel.2005.09.038. View